Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. - Lowery CD; Blosser W; Dowless M; Renschler M; Perez LV; Stephens J; Pytowski B; Wasserstrom H; Stancato LF; Falcon B (Oncotarget, 2019)